About Advaccine Biotechnology Co., Ltd
Advaccine Biotechnology Co., Ltd. (艾棣维欣生物) is a leading Chinese biopharmaceutical company specializing in innovative vaccine development and advanced drug delivery technologies. Recognized as a National High-Tech Enterprise, the company integrates cutting-edge antigen design, adjuvant innovation, and microneedle-based delivery platforms to address global health challenges.
Microneedle Innovation Leadership
Advaccine has pioneered microneedle technology through comprehensive capabilities spanning:
1. Formulation Screening & Analysis: Proprietary optimize antigen-adjuvant compatibility for thermostable microneedle arrays.
2. Quality Control Systems: Real-time monitoring ensures batch consistency with <5% dose variability across production lots.
3. GMP Process Development: Patented continuous manufacturing processes achieve high yield efficiency for microneedle patches.
4. Regulatory Milestone: Launched China's first FDA-approved OTC microneedle product in 2024.
Microneedle Innovation Leadership
Advaccine has pioneered microneedle technology through comprehensive capabilities spanning:
1. Formulation Screening & Analysis: Proprietary optimize antigen-adjuvant compatibility for thermostable microneedle arrays.
2. Quality Control Systems: Real-time monitoring ensures batch consistency with <5% dose variability across production lots.
3. GMP Process Development: Patented continuous manufacturing processes achieve high yield efficiency for microneedle patches.
4. Regulatory Milestone: Launched China's first FDA-approved OTC microneedle product in 2024.